Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

URGN

+ Watchlist+ Portfolio

UroGen Pharma Ltd.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$29.87
52-Week Range
$16.50 – $50.81
Market Cap
$1.46B
P/E (TTM)
—
EPS (TTM)
-1.31
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-8.46%
Gross Margin
91.41%
Operating Margin
-12.36%
Profit Margin
-26.27%
Current Ratio
3.40
Debt/Equity
—
Total Debt
$196.28M
Free Cash Flow
$-97.18M
Revenue Growth
223.90%
Earnings Growth
—
Enterprise Value
$1.57B

Market Snapshot

About

UroGen Pharma is a biopharmaceutical company developing treatments for urological cancers and diseases. The company specializes in RTGel technology, a proprietary sustained-release hydrogel formulation that enables prolonged exposure of urological tissues to therapeutic agents. UroGen focuses on bladder and upper urinary tract cancers.